Verastem Oncology (VSTM), which transitioned to a commercial-stage company in 2025 with the launch of Avmapki Fakzynja Co-Pack, is optimistic about driving sustainable growth this year.
Avmapki Fakzynja Co-Pack is a kinase inhibitor combination of avutometinib and defactinib, approved for the treatment of KRAS-mutated recurrent low-grade serous ovarian cancer. It was granted accelerated approval by the FDA in May 2025 and is the first-ever FDA-approved treatment for this indication.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com